Epperly Melissa B, Zentalis Pharmaceuticals, Inc. (ZNTL) insider trading activity

Epperly Melissa B, is Chief Financial Officer of Zentalis Pharmaceuticals, Inc.. Currently has a direct ownership of 451,449 shares of ZNTL, which is worth approximately $1.46 Million. The most recent transaction as insider was on Feb 12, 2024, when has been sold 2,573 shares (Common Stock) at a price of $11.44 per share, resulting in proceeds of $29,435. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 451K

0% 3M change

15.15% 12M change

Total Value Held $1.46 Million

Epperly Melissa B, Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 12 2024	SELL Open market or private sale	$29,435 $11.44 p/Share	2,573 Reduced 0.57%	451,449 Common Stock
Feb 02 2024	SELL Open market or private sale	$100,040 $11.54 p/Share	8,669 Reduced 1.87%	454,022 Common Stock
Feb 01 2024	BUY Grant, award, or other acquisition	-	75,000 Added 13.95%	462,691 Common Stock
Oct 04 2023	SELL Open market or private sale	$107,830 $19.67 p/Share	5,482 Reduced 1.39%	387,691 Common Stock
Feb 14 2023	SELL Open market or private sale	$104,435 $19.98 p/Share	5,227 Reduced 1.32%	392,048 Common Stock
Feb 13 2023	SELL Open market or private sale	$53,582 $20.42 p/Share	2,624 Reduced 0.66%	397,275 Common Stock
Feb 01 2023	BUY Grant, award, or other acquisition	-	101,957 Added 20.32%	399,899 Common Stock
Oct 03 2022	BUY Grant, award, or other acquisition	-	50,000 Added 14.39%	297,543 Common Stock
Apr 04 2022	SELL Open market or private sale	$866,981 $50.76 p/Share	17,080 Reduced 6.46%	247,414 Common Stock
Feb 23 2022	SELL Open market or private sale	$94,120 $49.2 p/Share	1,913 Reduced 0.72%	264,494 Common Stock
Feb 10 2022	BUY Grant, award, or other acquisition	-	16,405 Added 5.8%	266,407 Common Stock
Oct 02 2021	SELL Payment of exercise price or tax liability	$1,146,580 $67.13 p/Share	17,080 Reduced 6.4%	250,002 Common Stock
Aug 19 2021	BUY Open market or private purchase	$430,820 $52.0 p/Share	8,285 Added 3.01%	266,685 Common Stock
Aug 18 2021	BUY Open market or private purchase	$68,952 $52.0 p/Share	1,326 Added 0.51%	258,400 Common Stock
Jul 01 2021	SELL Open market or private sale	$159,114 $51.61 p/Share	3,083 Reduced 1.19%	257,074 Common Stock
Jun 01 2021	SELL Open market or private sale	$167,869 $54.45 p/Share	3,083 Reduced 1.17%	260,157 Common Stock
May 03 2021	SELL Open market or private sale	$181,126 $58.75 p/Share	3,083 Reduced 1.16%	263,240 Common Stock
Apr 05 2021	SELL Open market or private sale	$753,050 $44.02 p/Share	17,107 Reduced 6.04%	266,323 Common Stock
Mar 01 2021	SELL Open market or private sale	$128,469 $41.67 p/Share	3,083 Reduced 1.08%	283,430 Common Stock
Feb 11 2021	BUY Grant, award, or other acquisition	-	15,000 Added 4.97%	286,513 Common Stock
Feb 01 2021	SELL Open market or private sale	$116,815 $37.89 p/Share	3,083 Reduced 1.12%	271,513 Common Stock
Jan 04 2021	SELL Open market or private sale	$160,224 $51.97 p/Share	3,083 Reduced 1.11%	274,596 Common Stock
Dec 07 2020	SELL Open market or private sale	$341,752 $52.87 p/Share	6,464 Reduced 2.27%	277,679 Common Stock
Dec 04 2020	SELL Open market or private sale	$367,931 $50.96 p/Share	7,220 Reduced 2.48%	284,143 Common Stock
Dec 02 2020	SELL Open market or private sale	$159,638 $51.78 p/Share	3,083 Reduced 1.05%	291,363 Common Stock

Also insider at

ROIV

Roivant Sciences Ltd. Healthcare

KNTE

Kinnate Biopharma Inc. Healthcare

NAUT

Nautilus Biotechnology, Inc. Healthcare

Director

EMB